4455-09-8

Basic information

• Product Name: PENTAFLUOROBENZYL P-TOLUENESULFONATE
• Synonyms: 2-Phenylethyltosylate;4-methylbenzenesulfonic acid 2-phenylethyl ester;2-Phenylethyl p-Toluenesulfonate p-Toluenesulfonic Acid Phenethyl Ester p-Toluenesulfonic Acid 2-Phenylethyl Ester;Phenethyl p-Toluenesulfonate;2-PHENYLETHYL P-TOLUENESULFONATE;TIMTEC-BB SBB006308;PHENETHYL P-TOLUENESULFONATE;PFB-TOSYLATE
• CAS NO: 4455-09-8
• Molecular Formula: C₁₅H₁₆O₃S
• Molecular Weight: 276.35
• Mol File: 4455-09-8.mol

Chemical Properties

• Melting Point: 78 °C
• Boiling Point: 428.7°Cat760mmHg
• Flash Point: 213.1°C
• Appearance: /
• Density: 1.196g/cm³
• Vapor Pressure: 3.71E-07mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: PENTAFLUOROBENZYL P-TOLUENESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: PENTAFLUOROBENZYL P-TOLUENESULFONATE(4455-09-8)
• EPA Substance Registry System: PENTAFLUOROBENZYL P-TOLUENESULFONATE(4455-09-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 4455-09-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
PENTAFLUOROBENZYL P-TOLUENESULFONATE is used as a reagent for the conversion of alcohols to pentafluorobenzyl ethers, which is crucial in various organic synthesis processes.
Used in Pharmaceutical Synthesis:
PENTAFLUOROBENZYL P-TOLUENESULFONATE is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
PENTAFLUOROBENZYL P-TOLUENESULFONATE is used as a reagent in the production of agrochemicals, aiding in the creation of effective compounds for agricultural applications.
Used in Fine Chemicals Industry:
PENTAFLUOROBENZYL P-TOLUENESULFONATE is used as a component in the synthesis of fine chemicals, which are essential in various specialized applications, including fragrances, dyes, and other high-value products.

InChI:InChI=1/C15H16O3S/c1-13-7-9-15(10-8-13)19(16,17)18-12-11-14-5-3-2-4-6-14/h2-10H,11-12H2,1H3

Upstream product

• 60-12-8 2-phenylethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 104-15-4 toluene-4-sulfonic acid 
• 103-82-2 phenylacetic acid 
• 824-79-3 sodium 4-methylbenzenesulfinate 
• 14629-58-4 trimethyl(phenethyloxy)silane 
• 455-16-3 p-toluenesulfonyl fluoride 
• 101-41-7 benzeneacetic acid methyl ester 

Downstream Products

• 1861-04-7 2-deuterioethylbenzene 
• 17376-04-4 2-phenethyl iodide 
• 6992-22-9 2-Methyl-3-(2-phenethyl)thiazolinium-tosylat 
• 1077-16-3 hexylbenzene 
• 1718-50-9 1,5-diphenylpentane 
• 17314-92-0 (3,3-dimethylbutyl)benzene 
• 103-45-7 acetic acid phenethyl ester 
• 73992-37-7 1,5-Diphenyl-<3,3-D2>-pentan 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 21053-54-3 1-(2-phenylethyl)imidazolidin-2-one 
• 74996-68-2 1,3-bis(2-phenylethyl)imidazolidin-2-one 
• 78377-93-2 dimethyl N-(2-phenylethyl)sulphoximide 
• 76803-75-3 ethyl 2-methyl-4-phenyl-2-(2'-propenyl)butyrate 
• 76803-77-5 ethyl 2-methyl-4-phenyl-2-vinylbutyrate 

Relevant articles and documents

Rational design of superoxide dismutase (sod) mimics: The evaluation of the therapeutic potential of new cationic Mn porphyrins with linear and cyclic substituents

Our goal herein has been to gain further insight into the parameters which control porphyrin therapeutic potential. Mn porphyrins (MnTnOct-2-PyP5+, MnTnHexOE-2-PyP5+, MnTE-2-PyPhP5+, and MnTPhE-2-PyP5+) that bea

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction

Disruption of EZH2-embryonic ectoderm development (EED) protein-protein interaction (PPI) is a new promising cancer therapeutic strategy. We have previously reported the discovery of astemizole, a small-molecule inhibitor targeting the EZH2-EED PPI. Herein, we report the cocrystal structure of EED in complex with astemizole at 2.15 ?. The structure elucidates the detailed binding mode of astemizole to EED and provides a structure-guided design for the discovery of a novel EZH2-EED interaction inhibitor, DC-PRC2in-01, with an affinityKdof 4.56 μM. DC-PRC2in-01 destabilizes the PRC2 complex, thereby leading to the degradation of PRC2 core proteins and the decrease of global H3K27me3 levels in cancer cells. The proliferation of PRC2-driven lymphomas cells is effectively inhibited, and the cell cycle is arrested in the G0/G1 phase. Together, these data demonstrate that DC-PRC2in-01 could be an effective chemical probe for investigating the PRC2-related physiology and pathology and providing a promising chemical scaffold for further development.

Preparation method of mirabilone related substance and intermediate thereof

The invention relates to the technical field of drug synthesis. The invention provides a preparation method of mirabilone related substance and an intermediate thereof. To the invention, the phenylethanol alcohol and the sulfonyl chloride compound are fir

Synthesis and evaluation of tetrahydroisoquinoline derivatives against Trypanosoma brucei rhodesiense

Human African Trypanosomiasis (HAT) is a neglected tropical disease caused by the parasitic protozoan Trypanosoma brucei (T. b.), and affects communities in sub-Saharan Africa. Previously, analogues of a tetrahydroisoquinoline scaffold were reported as having in vitro activity (IC50 = 0.25–70.5 μM) against T. b. rhodesiense. In this study the synthesis and antitrypanosomal activity of 80 compounds based around a core tetrahydroisoquinoline scaffold are reported. A detailed structure activity relationship was revealed, and five derivatives (two of which have been previously reported) with inhibition of T. b. rhodesiense growth in the sub-micromolar range were identified. Four of these (3c, 12b, 17b and 26a) were also found to have good selectivity over mammalian cells (SI > 50). Calculated logD values and preliminary ADME studies predict that these compounds are likely to have good absorption and metabolic stability, with the ability to passively permeate the blood brain barrier. This makes them excellent leads for a blood-brain barrier permeable antitrypanosomal scaffold.

GRP94 SELECTIVE INHIBITORS AND USES THEREOF

The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.

Carbon glucoside sodium glucose transport protein body 2 inhibitor

The invention relates to a carbon glucoside sodium glucose transport protein body 2 inhibitor, a preparation method and an application of the inhibitor. The carbon glucoside sodium glucose transport protein body 2 inhibitor has a structure as shown in general formula (I) as shown in the specification.

Regioselective pinacol rearrangement of unsymmetrical cyclobutane-1,2-diols

Hydroxy-sulfone 34b, prepared as a mixture of trans and cis isomers by condensing the O-silyl derivative 18c of 2-hydroxy-2-methyl-cyclobutanone 18b-the Norrish II photocyclisation product of 2,3-pentanedione 21- and methyl phenyl sulfone 33 was found to rearrange selectively either to the cyclo-propanic β-ketosulfone 37 or the isomeric methyl ketone 38 by using, respectively, the tosyl fluoride/DBU and the DAST reagent. The potential of this methodology has been illustrated by a synthesis of phytal 1 from geranylacetone 46, and by the preparation from 3,4-hexanedione 51 and prenol 56-via the cyclopropanic β-ketosulfone 54 (X-ray)-of an advanced fragment of the juvenile hormone molecule 59.

Rapid transformation of sulfinate salts into sulfonates promoted by a hypervalent iodine(III) reagent

An alternative method for forming sulfonates through hypervalent iodine(III) reagent-mediated oxidation of sodium sulfinates has been developed. This transformation involves trapping reactive sulfonium species using alcohols. With additional optimization of the reaction conditions, the method appears extendable to other nucleophiles such as electron-rich aromatic systems or cyclic ethers through a ring opening pathway.

Ionic liquid brush as an efficient and reusable heterogeneous catalytic assembly for the tosylation of phenols and alcohols in neat water

A very efficient and reusable heterogeneous ionic liquid brush assembly was developed. The catalyst exhibits high catalytic activity for the tosylation of phenols and alcohols in neat water. Moreover, the catalyst shows outstanding stability and reusability, and it can be simply and effectively recovered and reused five times without noticeable loss of catalytic activity.

TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers or congenital diseases. Specific cancers and congenital disease includes those that are mediated by YAP/TAZ.